[go: up one dir, main page]

AR100886A1 - 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas - Google Patents

3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas

Info

Publication number
AR100886A1
AR100886A1 ARP150101931A ARP150101931A AR100886A1 AR 100886 A1 AR100886 A1 AR 100886A1 AR P150101931 A ARP150101931 A AR P150101931A AR P150101931 A ARP150101931 A AR P150101931A AR 100886 A1 AR100886 A1 AR 100886A1
Authority
AR
Argentina
Prior art keywords
alkyl
independently
case
optionally substituted
phenyl
Prior art date
Application number
ARP150101931A
Other languages
English (en)
Inventor
Dr Graubaum Heinz
Dr Blint Jozsef
Dr Sonnenschein Helmut
Dr Tempel Rene
Dr Lienau Philip
Dr Holton Simon
Dr Bone Wilhelm
Dr Siemeister Gerhard
Dr Schulze Volker
Dr Eis Knut
Dr Brfacker Lars
Dr Hitchcock Marion
Dr Briem Hans
Dr Graham Keith
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of AR100886A1 publication Critical patent/AR100886A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Son inhibidores de la quinasa Bub1, procesos para su producción y su uso como compuestos farmacéuticos. Reivindicación 1: Un compuesto caracterizado porque es de fórmula (1) en donde: R¹ representa hidrógeno, C₁₋₄-alquilo, C₁₋₄-haloalquilo, C₃₋₆-cicloalquilo, o fenilo, donde dicho fenilo está opcionalmente sustituido, una o más veces, en forma independiente en cada caso, con R³, donde dicho C₃₋₆-cicloalquilo está opcionalmente sustituido, una o más veces, en forma independiente en cada caso, con halógeno; y R² representa hidrógeno, C₁₋₄-alquilo o C₁₋₄-haloalquilo; o R¹ y R² junto con el átomo de carbono al cual se encuentran unidos forman un anillo cicloalquilo de entre 3 y 7 miembros; y el anillo A representa un grupo seleccionado entre el grupo de fórmulas (2), donde * indica el punto de unión de dicho grupo con el resto de la molécula y dicho grupo está opcionalmente sustituido, una o más veces, en forma independiente en cada caso, con R³; y G¹ representa O, S, o NR²¹; G², G³ representan, en forma independiente entre sí, CR²¹ o N; R³ representa hidrógeno, halógeno, hidroxi, amino, nitro, ciano, C₁₋₄-alquilo, C₃₋₆-cicloalquilo, C₂₋₄-alquenilo, C₂₋₄-alquinilo, C₁₋₄-alcoxi, C₁₋₄-alcoxi-C₁₋₄-alquilo, C₁₋₄-haloalquilo, C₁₋₄-haloalcoxi, C₁₋₄-alquil-C(O)-, R¹⁸-O-C(O)-, R⁷R⁸N-C(O)-, C₁₋₄-alquil-C(O)-NH-, R⁷R⁸N-, R⁷R⁸N-SO₂-, o un grupo seleccionado entre el grupo de fórmulas (3), donde * indica el punto de unión de dicho grupo con el resto de la molécula; donde dichos grupos C₁₋₄-alquilo, C₁₋₄-alcoxi, C₁₋₄-haloalquilo o C₁₋₄-haloalcoxi están opcionalmente sustituidos con uno o dos grupos hidroxi; y G⁴ representa O, S, o NR²¹; G⁵, G⁶ representan, en forma independiente entre sí, CR²¹ o N; R⁶ representa, en forma independiente en cada caso, halógeno, hidroxi, amino, nitro, ciano, C₁₋₄-alquilo, C₁₋₄-alcoxi, C₁₋₄-alcoxi-C₁₋₄-alquilo, C₁₋₄-haloalquilo o C₁₋₄-haloalcoxi; y el anillo B representa un grupo seleccionado entre el grupo de fórmulas (4), donde * indica el punto de unión de dicho grupo con el resto de la molécula; y X representa CR⁴ o N; e Y representa CR⁴ o N, donde cuando uno de X e Y representa N, el otro representa CR⁴; y R⁴ representa, en forma independiente en cada caso, hidrógeno, halógeno, hidroxi, ciano, C₁₋₄-alquilo, C₃₋₄-cicloalquilo, C₁₋₄-alcoxi, C₁₋₄-alquil-S-, C₁₋₄-alquil-SO-, C₁₋₄-alquil-SO₂-, R⁹R¹⁰N-, R¹¹-C(O)-(NR⁷)-, (R¹¹-C(O)-)(R¹²-C(O)-)N-, R⁹R¹⁰N-C(O)-(NR⁷)-, R⁹R¹⁰N-C(S)-(NR⁷)-, R¹⁸-O-C(O)-(NR⁷)-, R⁹R¹⁰N-SO₂- o C₁₋₄-alquil-SO₂-NH-, donde dicho C₁₋₄-alquilo está opcionalmente sustituido, una o más veces, en forma independiente en cada caso, con un sustituyente seleccionado entre hidroxi y halógeno; y donde dicho C₁₋₄-alcoxi está opcionalmente sustituido, una o más veces, en forma independiente en cada caso, con un sustituyente seleccionado entre hidroxi, halógeno, C₁₋₄-alcoxi, C₃₋₆-cicloalquilo y fenilo, donde dicho fenilo está opcionalmente sustituido, una o más veces, en forma independiente en cada caso, con R³; y donde dicho C₃₋₄-cicloalquilo está opcionalmente sustituido, una o más veces, en forma independiente en cada caso, con halógeno; R⁵ representa, en forma independiente en cada caso, halógeno, hidroxi, amino, nitro, ciano, C₁₋₄-alquilo, C₃₋₆-cicloalquilo, C₁₋₄-alcoxi, C₁₋₄-haloalquilo, C₁₋₄-haloalcoxi o fenil-C₁₋₄-alquilo, donde dicho grupo fenilo está opcionalmente sustituido, una o más veces, en forma independiente en cada caso, con un sustituyente seleccionado entre halógeno, hidroxi, C₁₋₃-alquilo, C₁₋₃-haloalquilo y C₁₋₃-alcoxi; donde dicho grupo C₃₋₆-cicloalquilo está opcionalmente sustituido, una o más veces, en forma independiente en cada caso, con halógeno; y J representa hidrógeno o hidroxi; y E representa hidrógeno, C₁₋₄-alquilo, C₁₋₄-alcoxi-C₂₋₄-alquilo, R¹⁷ᵃR¹⁷ᵇR¹⁷ᶜSi-O-C₂₋₄-alquilo, C₁₋₄-alquil-SO₂-C₁₋₄-alquilo, R¹⁸-O-C(O)-C₁₋₄-alquilo, R⁷R⁸N-C₂₋₄-alquilo, R⁷R⁸N-C(O)-C₁₋₄-alquilo o fenil-C₁₋₄-alquilo, donde dicho C₁₋₄-alquilo está opcionalmente sustituido, una o más veces, en forma independiente en cada caso, con un sustituyente seleccionado entre hidroxi y halógeno; y donde dicho grupo fenilo está opcionalmente sustituido, una o más veces, en forma independiente en cada caso, con R⁵; Q representa O ó N-OR¹⁶; R⁷, R⁸ representan, en forma independiente entre sí, hidrógeno, C₁₋₄-alquilo o tert-butil-O-C(O)-; y R⁹, R¹⁰ representan, en forma independiente entre sí, hidrógeno, C₁₋₄-alquilo, C₃₋₆-cicloalquilo, C₁₋₄-haloalquilo, fenilo o heteroarilo, donde dicho grupo fenilo o heteroarilo está opcionalmente sustituido, una o más veces, en forma independiente en cada caso, con R⁵; y donde dicho C₁₋₄-alquilo está opcionalmente sustituido, una o más veces, en forma independiente en cada caso, con un sustituyente seleccionado entre hidroxi, C₁₋₄-alcoxi, C₁₋₄-alquil-S-, C₃₋₆-cicloalquilo, heterocicloalquilo de entre 4 y 6 miembros, fenilo, heteroarilo y R¹⁸-O-C(O)-, donde dicho C₃₋₆-cicloalquilo o heterocicloalquilo de entre 4 y 6 miembros está opcionalmente sustituido, una o más veces, en forma independiente en cada caso, con un sustituyente seleccionado entre halógeno, C₁₋₄-alquilo y tert-butil-O-C(O)-, donde dicho grupo fenilo o heteroarilo está opcionalmente sustituido, una o más veces, en forma independiente en cada caso, con R⁵; o R⁹ y R¹⁰ junto con el átomo de nitrógeno al cual están unidos forman un anillo heterocíclico de entre 3 y 7 miembros que contiene nitrógeno, que contiene opcionalmente un heteroátomo adicional seleccionado entre O, NH o S, y que puede estar sustituido opcionalmente, una o más veces, en forma independiente en cada caso, con R⁵; y R¹¹, R¹² representan, en forma independiente entre sí, C₁₋₄-alquilo, C₂₋₄-alquenilo, C₂₋₄-alquinilo, C₃₋₆-cicloalquilo, heterocicloalquilo de entre 4 y 6 miembros, fenilo, heteroarilo, o R¹³-(C₁₋₄-alquil)-O-CH₂-, donde dicho C₁₋₄-alquilo está opcionalmente sustituido, una o más veces, en forma independiente en cada caso, con un sustituyente seleccionado entre halógeno, hidroxi, ciano, C₁₋₄-alcoxi, R⁷R⁸N-, R¹⁴, R¹⁵-O-, y fenilo opcionalmente sustituido, una o más veces, en forma independiente en cada caso, con R⁵, y donde dicho C₃₋₆-cicloalquilo está opcionalmente sustituido, una o más veces, en forma independiente en cada caso, con un sustituyente seleccionado entre halógeno, ciano, C₁₋₄-alquilo, C₁₋₄-haloalquilo y fenilo opcionalmente sustituido, una o más veces, en forma independiente en cada caso, con R⁵, y donde dicho heterocicloalquilo de entre 4 y 6 miembros está opcionalmente sustituido, una o más veces, en forma independiente en cada caso, con un sustituyente seleccionado entre hidroxi, C₁₋₄-alquilo, C₁₋₄-alcoxi, R⁷R⁸N- y R¹⁸-O-C(O)-, y donde dicho fenilo o heteroarilo está opcionalmente sustituido, una o más veces, en forma independiente en cada caso, con R⁵; R¹³ representa C₃₋₄-alquilo ramificado, C₁₋₄-haloalquilo, C₂₋₄-alquenilo, C₂₋₄-alquinilo, C₃₋₆-cicloalquilo, heterocicloalquilo de entre 4 y 6 miembros, fenilo o heteroarilo, donde dicho fenilo o heteroarilo está opcionalmente sustituido, una o más veces, en forma independiente en cada caso, con R⁵; R¹⁴ representa C₁₋₄-alquil-S-, C₁₋₄-alquil-SO₂-, C₃₋₆-cicloalquilo, heterocicloalquilo de entre 4 y 6 miembros, fenilo o heteroarilo, donde dicho fenilo o heteroarilo está opcionalmente sustituido, una o más veces, en forma independiente en cada caso, con R⁵; R¹⁵ representa fenilo o heteroarilo, donde dicho fenilo o heteroarilo está opcionalmente sustituido, una o más veces, en forma independiente en cada caso, con R⁵; y R¹⁶ representa hidrógeno, C₁₋₆-alquilo, fenilo o C₁₋₄-alquil-C(O)-, donde dicho grupo fenilo está opcionalmente sustituido, una o más veces, en forma independiente en cada caso, con R⁵; R¹⁷ᵃ, R¹⁷ᵇ, R¹⁷ᶜ, representan, en forma independiente entre sí, C₁₋₄-alquilo; R¹⁸ representa hidrógeno o C₁₋₆-alquilo; R²¹ representa hidrógeno, C₁₋₄-alquilo, C₁₋₄-haloalquilo, o C₁₋₆-cicloalquilo opcionalmente sustituido, una o más veces, en forma independiente en cada caso, con halógeno; R²² representa hidrógeno, halógeno, C₁₋₄-alquilo, C₁₋₄-haloalquilo, o C₁₋₆-cicloalquilo opcionalmente sustituido, una o más veces, en forma independiente en cada caso, con halógeno; m representa 0, 1 ó 2; n representa 0, 1, 2 ó 3; o un N-óxido, una sal, un tautómero o un estereoisómero de dicho compuesto, o una sal de dicho N-óxido, tautómero o estereoisómero.
ARP150101931A 2014-06-17 2015-06-17 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas AR100886A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14172850 2014-06-17

Publications (1)

Publication Number Publication Date
AR100886A1 true AR100886A1 (es) 2016-11-09

Family

ID=50972534

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150101931A AR100886A1 (es) 2014-06-17 2015-06-17 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas

Country Status (10)

Country Link
US (1) US10428044B2 (es)
EP (1) EP3157914B1 (es)
JP (1) JP6545199B2 (es)
CN (1) CN106715415B (es)
AR (1) AR100886A1 (es)
CA (1) CA2952307A1 (es)
ES (1) ES2708211T3 (es)
TW (1) TW201613886A (es)
UY (1) UY36175A (es)
WO (1) WO2015193339A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6704398B2 (ja) * 2015-01-28 2020-06-03 バイエル ファーマ アクチエンゲゼルシャフト ４Ｈ−ピロロ［３，２−ｃ］ピリジン−４−オン誘導体
CA2989469A1 (en) * 2015-06-17 2016-12-22 Bayer Pharma Aktiengesellschaft 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones
CN107921286A (zh) 2015-08-05 2018-04-17 拜耳制药股份公司 1h‑吡咯‑3‑胺类化合物
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
WO2018122168A1 (en) 2016-12-29 2018-07-05 Bayer Pharma Aktiengesellschaft Combinations of bub1 kinase and parp inhibitors
WO2018158175A1 (en) 2017-02-28 2018-09-07 Bayer Pharma Aktiengesellschaft Combination of bub1 inhibitors
WO2018206547A1 (en) 2017-05-12 2018-11-15 Bayer Pharma Aktiengesellschaft Combination of bub1 and atr inhibitors
WO2018215282A1 (en) 2017-05-26 2018-11-29 Bayer Pharma Aktiengesellschaft Combination of bub1 and pi3k inhibitors
EP3700904B1 (en) 2017-10-24 2023-07-19 Bayer AG 4h-pyrrolo[3,2-c]pyridin-4-one derivatives
US20220378762A1 (en) 2019-04-24 2022-12-01 Bayer Aktiengesellschaft 4h-pyrrolo[3,2-c]pyridin-4-one derivatives
WO2020216773A1 (en) 2019-04-24 2020-10-29 Bayer Aktiengesellschaft 4h-pyrrolo[3,2-c]pyridin-4-one compounds
CR20210530A (es) 2019-04-24 2021-12-23 Broad Inst Inc Compuestos de 4h-pirrolo[3,2-c]piridin-4-ona
CA3177214A1 (en) 2020-03-31 2021-10-07 Bayer Aktiengesellschaft 3-(anilino)-2-[3-(3-alkoxy-pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one derivatives as egfr inhibitors for the treatment of cancer
CA3196712A1 (en) 2020-09-23 2022-03-31 Scorpion Therapeutics, Inc. Pyrrolo[3,2-c]pyridin-4-one derivatives useful in the treatment of cancer
WO2022072634A1 (en) 2020-09-30 2022-04-07 Scorpion Therapeutics, Inc. Bicyclic compounds for use in the treatment cancer
WO2022072645A2 (en) 2020-09-30 2022-04-07 Scorpion Therapeutics, Inc. Methods for treating cancer
BR112023006531A2 (pt) 2020-10-09 2023-10-03 Scorpion Therapeutics Inc Inibidores heterocílicos de egfr e/ou her2, para uso no tratamento de câncer
WO2022094271A1 (en) 2020-10-30 2022-05-05 Scorpion Therapeutics, Inc. Methods for treating cancer
WO2022098992A1 (en) 2020-11-05 2022-05-12 Scorpion Therapeutics, Inc. Use of macrocyclic compounds in methods of treating cancer
WO2022197913A1 (en) 2021-03-18 2022-09-22 Scorpion Therapeutics, Inc. Bicyclic derivatives which can be used to treat cancer
WO2023173083A1 (en) 2022-03-11 2023-09-14 Scorpion Therapeutics, Inc. Tetrahydroindole derivatives as egfr and/or her2 inhibtors useful for the treatment of cancer
EP4293019A1 (en) * 2022-06-13 2023-12-20 Netherlands Translational Research Center Holding B.V. 4-substituted (1h-benzo[d]imidazol-2-yl)-1h-pyrazoles as bub1 inhibitors useful for treating cancers
WO2024254266A1 (en) 2023-06-08 2024-12-12 Scorpion Therapeutics, Inc. A 1,5-dihydro-4h-pyrrolo[3,2-c] pyridin-4-one for use in the treatment of cancer
WO2024254298A1 (en) 2023-06-08 2024-12-12 Scorpion Therapeutics, Inc. A 1,5-dihydro-4h-pyrrolo[3,2-c] pyridin-4-one for use in the treatment of cancer

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3720711A (en) * 1971-11-02 1973-03-13 American Home Prod Derivatives of 6-oxo-1-cyclohexene-1-carboxamide
JP3455230B2 (ja) * 1996-07-11 2003-10-14 ファイザー製薬株式会社 インターロイキン―およびｔｎｆアンタゴニストとして有用なピリジルピロール化合物
WO1998002430A1 (en) 1996-07-11 1998-01-22 Pfizer Pharmaceuticals Inc. Pyridylpyrrole compounds useful as interleukin- and tnf antagonists
GB9812038D0 (en) * 1998-06-04 1998-07-29 Merck Sharp & Dohme Therapeutic compound
JP2000063354A (ja) 1998-08-21 2000-02-29 Sumitomo Pharmaceut Co Ltd ピロール誘導体
WO2003073999A2 (en) * 2002-03-01 2003-09-12 Pintex Pharmaceuticals, Inc. Pini-modulating compounds and methods of use thereof
US20120232062A1 (en) 2009-10-20 2012-09-13 Eiger Biopharmaceuticals, Inc. Azaindazoles to treat flaviviridae virus infection
WO2011115804A1 (en) 2010-03-17 2011-09-22 Ironwood Pharmaceuticals, Inc. Sgc stimulators
CN102918034B (zh) 2010-03-30 2015-06-03 维颂公司 多取代芳族化合物作为凝血酶的抑制剂
DK2588465T3 (en) 2010-06-30 2017-05-01 Ironwood Pharmaceuticals Inc SGC stimulators
UA111754C2 (uk) * 2011-10-06 2016-06-10 Байєр Фарма Акцієнгезелльшафт Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань
CN104125957B (zh) 2011-12-21 2016-05-25 拜耳知识产权有限责任公司 取代的苄基吡唑
CA2861804C (en) 2011-12-27 2021-10-26 Ironwood Pharmaceuticals, Inc. 2-benzyl,3(pyrimidin-2-yl)substituted pyrazoles useful as sgc stimulators
EP2847180B1 (en) * 2012-05-11 2017-01-04 Bayer Pharma Aktiengesellschaft Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer
WO2014047111A1 (en) 2012-09-18 2014-03-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
WO2014047325A1 (en) 2012-09-19 2014-03-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
CA2907594A1 (en) 2013-03-21 2014-09-25 Bayer Pharma Aktiengesellschaft Heteroaryl substituted indazoles
JP2016514718A (ja) 2013-03-21 2016-05-23 バイエル ファーマ アクチエンゲゼルシャフト ３−ヘテロアリール置換インダゾール類
JP2016514717A (ja) 2013-03-21 2016-05-23 バイエル ファーマ アクチエンゲゼルシャフト ジアミノヘテロアリール置換インダゾール
JP2016526540A (ja) 2013-06-21 2016-09-05 バイエル ファーマ アクチエンゲゼルシャフト 置換ベンジルピラゾール
CA2916103A1 (en) 2013-06-21 2014-12-24 Bayer Pharma Aktiengesellschaft Diaminoheteroaryl substituted pyrazoles
ES2652305T3 (es) 2013-06-21 2018-02-01 Bayer Pharma Aktiengesellschaft Pirazoles heteroaril sustituidos
EP3010904A1 (en) 2013-06-21 2016-04-27 Bayer Pharma Aktiengesellschaft Substituted benzylpyrazoles
HK1223097A1 (zh) 2013-06-21 2017-07-21 Bayer Pharma Aktiengesellschaft 雜芳基取代的吡唑
CA2961570A1 (en) 2014-09-19 2016-03-24 Lars Barfacker Benzyl substituted indazoles
EP3194380A1 (en) 2014-09-19 2017-07-26 Bayer Pharma Aktiengesellschaft Benzyl substituted indazoles as bub1 kinase inhibitors
EP3194381A1 (en) 2014-09-19 2017-07-26 Bayer Pharma Aktiengesellschaft Benzyl substituted indazoles as bub1 kinase inhibitors
PE20170697A1 (es) 2014-09-19 2017-06-24 Bayer Pharma AG Indazoles sustituidos con benzilo como inhibidores de bub1
JP6704398B2 (ja) 2015-01-28 2020-06-03 バイエル ファーマ アクチエンゲゼルシャフト ４Ｈ−ピロロ［３，２−ｃ］ピリジン−４−オン誘導体
CA2989469A1 (en) * 2015-06-17 2016-12-22 Bayer Pharma Aktiengesellschaft 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones
CN107921286A (zh) 2015-08-05 2018-04-17 拜耳制药股份公司 1h‑吡咯‑3‑胺类化合物

Also Published As

Publication number Publication date
CN106715415B (zh) 2019-06-14
CN106715415A (zh) 2017-05-24
JP6545199B2 (ja) 2019-07-17
US10428044B2 (en) 2019-10-01
TW201613886A (en) 2016-04-16
CA2952307A1 (en) 2015-12-23
WO2015193339A1 (en) 2015-12-23
EP3157914A1 (en) 2017-04-26
US20170101391A1 (en) 2017-04-13
ES2708211T3 (es) 2019-04-09
JP2017526622A (ja) 2017-09-14
UY36175A (es) 2016-01-29
EP3157914B1 (en) 2018-09-26

Similar Documents

Publication Publication Date Title
AR100886A1 (es) 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
PE20190656A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
AR103561A1 (es) Fenilpiridinas herbicidas
AR104513A1 (es) Derivados de ciclohexano sustituidos con amidas como inhibidores de tnks1 y/o tnks2
AR104025A1 (es) Carbamatos de piperazina como moduladores de magl y/o abhd6, procesos para su preparación y composiciones farmacéuticas
PE20171240A1 (es) Derivados de 4h-pirrol[3,2-c]piridin-4-ona
AR104487A1 (es) Compuestos de quinolina
AR100438A1 (es) Pirazolopiridinas y pirazolopirimidinas
AR088449A1 (es) Benzilindazoles sustituidos
AR101179A1 (es) Combinaciones anti-pd-l1 para tratar tumores
AR082799A1 (es) Derivados de quinolina y quinoxalina como inhibidores de quinasa
AR100806A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR100810A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR088029A1 (es) Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central
AR106301A1 (es) Composiciones de pirrolpirimidina como inhibidores de quinasas
AR090572A1 (es) Derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticos
AR098492A1 (es) Derivados de purina
AR091261A1 (es) Derivados de alcoholes 1-fenil-2-piridinilalquilicos como inhibidores de la fosfodiesterasa
MX2017011650A (es) Inhibidores de kv1.3 y su aplicacion medica.
AR097755A1 (es) Derivados sustituidos de fenilalanina como moduladores del factor xia
AR104856A1 (es) Derivados de difluorocetamida
AR097754A1 (es) Derivados sustituidos de fenilalanina
AR096614A1 (es) Moduladores de la acetil-coa carboxilasa
JOP20170115B1 (ar) مشتقات بيريدينيل، تركيبات صيدلية منها واستخداماتها كمثبطات aoc3
AR105460A1 (es) Derivados sustituidos de 2-pirimidina furano / tienocicloalquilamino y su uso para el control del crecimiento de plantas no deseables

Legal Events

Date Code Title Description
FB Suspension of granting procedure